Friday, July 5, 2013

EU approves Novartis eye drug for new use

Related News

  • For blind campers, a first chance to swim and canoe

    Wed, Jul 3 2013

  • Swiss stocks - Factors to watch on June 26

    Wed, Jun 26 2013

A man speaks on a telephone inside Novartis India headquarters in Mumbai April 1, 2013. REUTERS/Vivek Prakash

A man speaks on a telephone inside Novartis India headquarters in Mumbai April 1, 2013.

Credit: Reuters/Vivek Prakash

ZURICH | Fri Jul 5, 2013 2:18am EDT

ZURICH (Reuters) - Swiss drugmaker Novartis' eye drug Lucentis has been approved as a treatment for a further condition related to worsening eyesight by the European Union, adding to three other conditions for which it is already approved.

The Basel-based drugmaker said the European Commission had granted approval for Lucentis to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia.

Lucentis, which was first launched in 2006, is an important product for Novartis and had sales of $2.4 billion in 2012.

The drug is already approved in the EU to treat wet age-related macular degeneration, visual impairment due to diabetic macular edema, and visual impairment due to macular edema secondary to retinal vein occlusion.

(Reporting by Caroline Copley; editing by Patrick Graham)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/

Comments (0)

Be the first to comment on reuters.com.

Add yours using the box above.


Source : http://feeds.reuters.com/~r/reuters/healthNews/~3/JOUt_3-vMoI/story01.htm

Posted by at